GO
Loading...

Medicine

More

  • North Korea lifts Ebola travel restrictions Tuesday, 3 Mar 2015 | 7:09 AM ET

    TOKYO— North Korea has lifted severe restrictions on foreign travel it imposed last year to keep the Ebola virus from crossing its borders. One tour company that takes tourists into North Korea, Uri Tours, said on its website Tuesday that it had been told by the country's national airline that the ban had been lifted. North Korea's decision to set the restrictions...

  • Sirleaf told fellow regional leaders and delegates at an international conference on Ebola in Brussels that restoring economic growth in Liberia, Guinea and Sierra Leone is a long-term and costly task. She said that "the most important long-term response to Ebola rests on plans and strategies for economic recovery," adding that "this will require significant...

  • Biotech drugmaker Amgen Inc.' s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company. Amgen, based in Thousand Oaks, California, on Sunday released interim results from its study. The Amgen- funded study, known by the acronym ENDEAVOR, included 929 patients who had relapsed after...

  • Cancer drug shows promise  Monday, 2 Mar 2015 | 1:17 PM ET

    Amgen's cancer drug Kyprolis demonstrated positive results in a study against Takeda's Velcade. Dr. Sean Harper, Amgen, discusses the benefit risk equation for both drugs.

  • NEW YORK— Medical device maker Boston Scientific said Monday it will pay $1.6 billion to buy the men's health and prostate health business of Endo International. Boston Scientific said it is gaining treatments for enlarged prostate, urinary incontinence caused by stress, and erectile dysfunction, and said the business has about $130 million in adjusted...

  • Nurse who survived Ebola sues Dallas hospital system Monday, 2 Mar 2015 | 12:14 PM ET

    DALLAS— The Dallas hospital that treated the first patient to be diagnosed in the U.S. with Ebola lied to Congress when it said its staff was trained to handle the deadly virus, a nurse who contracted the disease contends in a lawsuit filed Monday. Nina Pham, who was an intensive care unit nurse at Texas Health Presbyterian Hospital Dallas, says after being told last...

  • Under the proposed settlement, Basic Research will pay a refund of $25 per box after being sued by law firms on behalf of consumers who purchased the product called Akavar beginning in 2007.. A Basic Research representative didn't respond to requests for comment. In 2007, a proposed class-action lawsuit was filed in U.S. District Court in Utah against Basic...

  • U.S., Liberia kick off trial of Ebola drug ZMapp Friday, 27 Feb 2015 | 12:50 PM ET

    CHICAGO, Feb 27- U.S. and Liberian researchers have started a clinical trial to test the safety and effectiveness of Mapp Biopharmaceutical Inc's Ebola drug ZMapp, an experimental treatment that has already been tried in a handful of Ebola patients, including two U.S. missionaries. The trial, a joint effort by the Liberian government and the National Institute...

  • Adults, as well as children of any age, will be enrolled in the study if they are admitted to Ebola treatment units in Liberia or are health care workers returning to the U.S. for treatment after being infected while serving in West Africa. That has happened to only two people— the nurses who treated patient Thomas Eric Duncan, who had traveled from Africa and died at a...

  • Actavis' contraceptive device wins U.S. FDA approval Friday, 27 Feb 2015 | 8:10 AM ET

    Feb 27- The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company...

  • Why antibiotics need innovation: Ezekiel Emanuel  Friday, 27 Feb 2015 | 7:18 AM ET

    We are losing the battle against bacteria, says Dr. Ezekiel Emanuel, University of Pennsylvania Medical Ethics Department, discussing the need to incentivize the development of new antibiotics.

  • TRENTON, N.J.— Drugmaker Bristol-Myers Squibb Co. said Thursday that an experimental combination of two hepatitis C drugs— its daclatasvir and Gilead Sciences Inc.' s blockbuster drug Sovaldi— cured hepatitis C in just 12 weeks in nearly all the patients, who also are infected with the HIV virus. David Wyles, an associate professor at University of...

  • Heat blamed for spray vaccine's failure against swine flu Thursday, 26 Feb 2015 | 12:53 PM ET

    ATLANTA— The makers of the nasal spray version of the flu vaccine say now they know why it has failed to protect young U.S. children against swine flu— fragile doses got too warm. The AstraZeneca FluMist vaccine works well for most flu strains, but small studies found it didn't work very well against the swine flu bug that first emerged in 2009. Swine flu has returned...

  • NEW YORK— You may think you're immune to transparent sales pitches like "Do you want fries with that?" But the tactics restaurants use to nudge you into spending a little extra may be subtler than you realize. Greg Rapp, a menu consultant in California, says he advises restaurants and fast-food chains to leave those off when listing prices on a menu.

  • Panel: Use new meningitis vaccines only for outbreaks Thursday, 26 Feb 2015 | 12:11 PM ET

    ATLANTA— A federal panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students. So the Advisory Committee on Immunization Practices declined to recommend routine shots for all adolescents and college students. One woman, Patti Wukovits from New...

  • Feb 26- Diagnostics company Corgenix Medical Corp said on Thursday U.S. health regulators had approved its rapid Ebola test for emergency use, in response to the world's worst outbreak of the virus that killed more than 10,000 so far. The company's ReEBOV Antigen Rapid Test, which involves putting a drop of blood on a paper strip and waiting for at least 15 minutes...

  • FDA approves Corgenix's Ebola test for emergency use Thursday, 26 Feb 2015 | 9:34 AM ET

    Feb 26- Corgenix Medical Corp said on Thursday the U.S. Food and Drug Administration approved its Ebola test for emergency use. The company's so-called ReEBOV Antigen Rapid Test involves putting a drop of blood on a small paper strip and waiting for 15-25 minutes for a reaction. The test is able to correctly identify about 92 percent of Ebola-infected patients...

  • Bayer is 'focusing on life sciences'  Thursday, 26 Feb 2015 | 6:00 AM ET

    Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • SYDNEY, Feb 26- Australian Prime Minister Tony Abbott backed plans on Thursday to introduce country-of-origin labelling in the wake of a hepatitis A outbreak, potentially risking contravention of World Trade Organization rules. Australia was among plaintiffs against the United States after it introduced its own stronger country-of-origin labelling...